- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 619
Atelerix stems from Newcastle research
The Northern Accelerator partnership of Durham University and Newcastle University has helped set up Atelerix, a human cell storage developer.
Sep 13, 2017WUSTL beats the drum for eight spinouts
Washington University in St Louis spun out eight companies during the past financial year and marked a 16% increase in novel invention disclosures.
Sep 13, 2017Sophia Genetics sources $30m
The Swisscom-backed genomic testing platform has now raised more than $60m, having closed a series D round led by Balderton Capital.
Sep 13, 2017Rani Therapeutics absorbs $39m
The oral drug technology developer, which is backed by corporates including Alphabet, Novartis and AstraZeneca, has now raised $100m in total.
Sep 13, 201723andMe cracks the code to raise $250m
The genetics services company, which is backed by Alphabet, Illumina, WuXi PharmaTech and Johnson and Johnson, has now raised more than $490m altogether.
Sep 13, 2017DNA Script reveals series A story
Merck Group and Illumina were among the investors in a $13.2m round, along with Idinvest Partners, Kurma Partners and existing backer Sofinnova Partners.
Sep 12, 2017Merck puts money into Antidote
Antidote Technologies, developer of a recruitment platform for clinical trials, has agreed an $11m round that will be led by Merck Global Health Innovation Fund.
Sep 11, 2017Talkspace enters $31m series C
Existing backer SoftBank has helped on-demand therapy service Talkspace close a $31m series C round that increased its total funding to $59m since 2014.
Sep 11, 2017ElectroCore powers up to raise $36m
Merck-backed nerve stimulation device producer ElectroCore has raised new funding, according to a securities filing that shows the company is seeking a $65m close.
Sep 11, 2017Amal develops $9.6m series B
University of Geneva spinout Amal Therapeutics has added $9.6m to its coffers following a series B round backed by Boehringer Ingelheim and Helsinn.
Sep 8, 2017About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


